Highly rated in
Highly rated in
Check Dr. Sushil Beriwal's experience treating your condition:
About Dr. Sushil Beriwal

Sushil Beriwal is a Radiation Oncologist in Pittsburgh, Pennsylvania. Beriwal has been practicing medicine for over 28 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Vulvar Cancer, Vaginal Cancer, Endometrial Cancer, Vulvectomy, and Orchiectomy. He is licensed to treat patients in Pennsylvania.

His clinical research consists of co-authoring 329 peer reviewed articles and participating in 8 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Sushil Beriwal it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
300 Halket St, Dept Of Radiation Oncology, Pittsburgh, PA 15213
Background & Education
Graduate Institution
Other, 1994
Radiation Oncology
Radiology in PA
Hospital Affiliations
UPMC McKeesport
UPMC Passavant - McCandless
UPMC St Margaret
UPMC Magee-Womens Hospital
UPMC Mercy
UPMC Presbyterian
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation (UPCI #10-027)
Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease (UPCI# 10-028)
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
View 6 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors